Spinal Cord Injury (SCI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Spinal Cord Injury (SCI) Market Outlook

Thelansis’s “Spinal Cord Injury (SCI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Spinal Cord Injury treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Spinal Cord Injury (SCI) Overview

A spinal cord injury (SCI) results from damage to the spinal cord, leading to temporary or permanent alterations in its functioning. SCI can be categorized into two main types: traumatic and non-traumatic. Traumatic SCI is the consequence of an external physical force that acutely injures the spinal cord, such as motor vehicle accidents, falls, sports-related injuries, or acts of violence. On the other hand, non-traumatic SCI is caused by acute or chronic diseases, such as tumors, infections, or degenerative disc disease, which initiate the primary injury. After a traumatic injury, first responders quickly assess and initiate care while transporting patients to the hospital, following advanced trauma life support protocols. This care includes airway, breathing, circulation support, and immobilizing the spinal column with a cervical collar and backboard. Trauma patients undergo neurological exams and spinal imaging if a spinal cord injury is suspected. Neurological recovery in SCI patients typically occurs within six months, with continued improvement up to five years. The prognosis depends on the initial injury severity and the level of the injury. Thoracic injuries, especially complete ones, have a lower potential for motor recovery due to challenges in detecting neurological improvement. Managing SCI is complex, spanning years and involving:

1. Emergency surgery for other traumas.
2. Rehabilitation for mobility and strength.
3. Use prostheses and medications to promote nerve cell regeneration or potentially improve nerve function.

Currently, there is no treatment to repair a damaged spinal cord.

• Between 250,000 and 500,000 people suffer from spinal cord injuries worldwide. There are approximately 17,000 to 18,000 new cases of SCI in the United States.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: